{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:07:49Z","timestamp":1778548069628,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,25]]},"DOI":"10.7759\/cureus.90964","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T18:16:57Z","timestamp":1756145817000},"source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Inflammatory Markers Among U.S. Adults: A National Health and Nutrition Examination Survey (NHANES)-Based Analysis"],"prefix":"10.7759","author":[{"given":"Sharokeen","family":"Youkhana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seun S","family":"Odusanmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno K","family":"Ihuchukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Ezekiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edidiong","family":"Enyeneokpon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Cumaaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel O","family":"Akpamgbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2016.08.026","article-title":"Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome","volume":"207","author":"Orio F","year":"2016","unstructured":"Orio F, Muscogiuri G, Nese C, et al.. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016, 207:214-9. 10.1016\/j.ejogrb.2016.08.026","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi SF","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al.. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023, 14:1148209. 10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman D","year":"2019","unstructured":"Furman D, Campisi J, Verdin E, et al.. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019, 25:1822-32. 10.1038\/s41591-019-0675-0","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1237729","article-title":"C-reactive protein: a target for therapy to reduce inflammation","volume":"14","author":"Rizo-T\u00e9llez SA","year":"2023","unstructured":"Rizo-T\u00e9llez SA, Sekheri M, Filep JG. C-reactive protein: a target for therapy to reduce inflammation. Front Immunol. 2023, 14:1237729. 10.3389\/fimmu.2023.1237729","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004554","article-title":"Prognostic importance of C-reactive protein in high cardiovascular risk patients with type 2 diabetes mellitus: the Rio de Janeiro type 2 diabetes cohort study","volume":"5","author":"Cardoso CR","year":"2016","unstructured":"Cardoso CR, Leite NC, Salles GF. Prognostic importance of C-reactive protein in high cardiovascular risk patients with type 2 diabetes mellitus: the Rio de Janeiro type 2 diabetes cohort study. J Am Heart Assoc. 2016, 5:004554. 10.1161\/JAHA.116.004554","journal-title":"J Am Heart Assoc"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2023.03.025","article-title":"C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations","volume":"197","author":"Burger PM","year":"2023","unstructured":"Burger PM, Pradhan AD, Dorresteijn JA, et al.. C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations. Am J Cardiol. 2023, 197:13-23.","journal-title":"Am J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-effects beyond obesity and diabetes","volume":"13","author":"Wilbon SS","year":"2023","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023, 13:65. 10.3390\/cells13010065","journal-title":"Cells"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13598","article-title":"Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: a prospective, observational study","volume":"12","author":"Kuwata H","year":"2021","unstructured":"Kuwata H, Yabe D, Murotani K, et al.. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: a prospective, observational study. J Diabetes Investig. 2021, 12:2162-71. 10.1111\/jdi.13598","journal-title":"J Diabetes Investig"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen RW","year":"2025","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025, 27:66-88. 10.1111\/dom.16364","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107 L","year":"2023","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Maci\u0107-D\u017eankovi\u0107 A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023, 4:1293926. 10.3389\/fcdhc.2023.1293926","journal-title":"Front Clin Diabetes Healthc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong CK","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, et al.. Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metab. 2024, 36:130-43.e5. 10.1016\/j.cmet.2023.11.009","journal-title":"Cell Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis","volume":"27","author":"Ren Y","year":"2025","unstructured":"Ren Y, Chen Y, Zheng W, et al.. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2025, 27:3607-26. 10.1111\/dom.16366","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas","volume":"18","author":"Smits MM","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016, 18:224-35. 10.1111\/dom.12593","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14100554","article-title":"Liraglutide therapy in obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress markers-a pilot study","volume":"14","author":"Bu\u0142dak \u0141","year":"2024","unstructured":"Bu\u0142dak \u0141, Bo\u0142dys A, Skudrzyk E, Machnik G, Okopie\u0144 B. Liraglutide therapy in obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress markers-a pilot study. Metabolites. 2024, 14:554. 10.3390\/metabo14100554","journal-title":"Metabolites"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp KO","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022, 186:106550. 10.1016\/j.phrs.2022.106550","journal-title":"Pharmacol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh S","year":"2017","unstructured":"Singh S, Wright EE Jr, Kwan AY, et al.. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017, 19:228-38. 10.1111\/dom.12805","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204.pub2","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","volume":"5","author":"Hemmingsen B","year":"2017","unstructured":"Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017, 5:CD012204. 10.1002\/14651858.CD012204.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000661","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: clinical evidence and best practice","volume":"34","author":"Coke LA","year":"2022","unstructured":"Coke LA, Deedwania PC, Hinnen D, Magwire M, Miller NH. GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: clinical evidence and best practice. J Am Assoc Nurse Pract. 2022, 34:418-40. 10.1097\/JXX.0000000000000661","journal-title":"J Am Assoc Nurse Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100624","article-title":"Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020","volume":"17","author":"Jacobs JA","year":"2024","unstructured":"Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress AP. Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. Am J Prev Cardiol. 2024, 17:100624. 10.1016\/j.ajpc.2023.100624","journal-title":"Am J Prev Cardiol"},{"key":"ref21","unstructured":"National Health and Nutrition Examination Survey (NHANES). (2025). Accessed. July 30, 2025: https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/search\/default.aspx."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403226-glucagon-like-peptide-1-glp-1-receptor-agonist-use-and-inflammatory-markers-among-us-adults-a-national-health-and-nutrition-examination-survey-nhanes-based-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T18:16:58Z","timestamp":1756145818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403226-glucagon-like-peptide-1-glp-1-receptor-agonist-use-and-inflammatory-markers-among-us-adults-a-national-health-and-nutrition-examination-survey-nhanes-based-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.90964","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}